Why Did a GLP-1 Receptor Agonist Fail This Parkinson’s Trial?

Source link : https://www.newshealth.biz/health-news/why-did-a-glp-1-receptor-agonist-fail-this-parkinsons-trial/

(MedPage Today) — Weekly injections of the GLP-1 receptor agonist exenatide (Byetta, Bydureon) did not slow Parkinson’s disease progression or improve symptoms, the phase III Exenatide-PD3 trial showed. At 96 weeks, mean Movement Disorder Society… Source link : https://www.medpagetoday.com/neurology/parkinsonsdisease/114113 Author : Publish date : 2025-02-06 20:35:02 Copyright for syndicated content belongs to the linked Source.

Author : News Health

Publish date : 2025-02-06 20:35:02

Copyright for syndicated content belongs to the linked Source.